US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

18.91

+0.25501.37%

Post-market: 18.910.00000.00%16:10 EDT

Volume:10.43K

Turnover:195.98K

Market Cap:109.70M

PE:- -

High:18.91

Open:18.83

Low:18.67

Close:18.66

52wk High:21.88

52wk Low:14.38

Shares:5.80M

Float Shares:5.80M

Volume Ratio:0.35

T/O Rate:0.18%

Dividend:0.71

Dividend Rate:3.78%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

BlackRock Expands Stake in INNOVENT BIO with Recent Share Purchase

CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Billion Yuan

Wuxi Biologics (Cayman) Stock Rises 2.3% in Hong Kong

WuXi Biologics Agrees to Sell 51.1% Stake in Bestchrom

JPMorgan Chase & Co. Increases Stake in BEONE MEDICINES by Over 4.1 Million Shares at Approximately HKD 219.79 Each

Everest Medicines Appoints Yue Wang as Non-Executive Director

Wuxi Biologics (Cayman) Stock Sheds 1.3% in Hong Kong

What Does Akeso (SEHK:9926) China Lung Cancer Approval Mean For Investors?

Simply Wall St.

Akari Net Loss Widens to $4.81 Million in Q2 FY26; Operating Loss Rises to $4.6 Million

Beone Medicines Awards Over 40,000 Restricted Stock Units to Employees

CSPC Pharmaceutical Group Stock Rallies 2.0% in Hong Kong, Outperforms Competitors

Akeso's Ivonescimab Gets Third Indication Approval in China

MT Newswires Live

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

Spero Q2 FY26 Net Loss Widens to $9.6 Million; Revenue Posts no Revenue

Akeso Says NMPA Approves Ivonescimab for 1L Treatment of SQ-NSCLC

CSPC Pharmaceutical Changes Trustee for 2018 Share Award Scheme to BOCI Trustee Hong Kong

Summit Gains After Partner Akeso Secures China Nod for Lung Cancer Combo

CSPC Pharmaceutical Group Announces Change in Trustee for 2018 Share Award Scheme

AKESO (09926) Gains NMPA Nod for Third Indication of Its First-in-Class Bispecific Antibody, Ivonescimab, in Frontline Squamous NSCLC

Akeso - Nmpa Approves Ivonescimab for 1L Treatment of Sq-Nsclc

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/KURE/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":18.91,"timestamp":1788465600000,"preClose":18.655,"halted":0,"volume":10429,"hourTrading":{"tag":"盘后","latestPrice":18.91,"preClose":18.91,"latestTime":"16:10 EDT","volume":10,"amount":189.1,"timestamp":1788466205561,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.013669257571696541,"floatShares":5800979,"shares":5800979,"eps":0,"marketStatus":"Post-Mkt","change":0.255,"latestTime":"09-03 17:01:26 EDT","open":18.83,"high":18.91,"low":18.6655,"amount":195976,"amplitude":0.013106,"askPrice":20.61,"askSize":100,"bidPrice":17.09,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788480000000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":18.655,"sharesOutstanding":4750002,"nav":18.46,"aum":108936686.05,"dividendRate":0.0378,"bidAskSpread":0.00342,"postHourTrading":{"tag":"盘后","latestPrice":18.91,"preClose":18.91,"latestTime":"16:10 EDT","volume":10,"amount":189.1,"timestamp":1788466205561,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.349371,"impliedVol":0.2767,"impliedVolPercentile":0.5754},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5800979,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.349371,"shares":5800979,"dividePrice":0.7148,"high":18.91,"amplitude":0.013106,"preClose":18.655,"low":18.6655,"week52Low":14.3797,"pbRate":"--","week52High":21.875,"institutionHeld":0,"latestPrice":18.91,"eps":0,"divideRate":0.0378,"volume":10429,"delay":0,"ttmEps":0,"open":18.83,"prevYearClose":17.04,"prevWeekClose":18.925,"prevMonthClose":18.54,"prevQuarterClose":15.747,"fiveDayClose":19.215,"twentyDayClose":17.47,"sixtyDayClose":14.5156},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1192028422","title":"BlackRock Expands Stake in INNOVENT BIO with Recent Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1192028422","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192028422?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:17","pubTimestamp":1786965461,"startTime":"0","endTime":"0","summary":"According to the latest disclosure from the Hong Kong Stock Exchange, BlackRock increased its shareholding in INNOVENT BIO (01801) on August 12, acquiring 139,500 shares at a price of HKD 95.375 per...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3PB1722.GBP","FDFF","IE00BGHQF748.EUR","LU0772969993.USD","BK4581","IE00BVYPNW00.USD","01801","BK1589","BK4504","LU1366333091.USD","BK4533","LU0130102774.USD","LU1969619763.USD","LU1989771016.USD","LU2430703095.HKD","BK4135","BK4585","LU2430703251.USD","LU0742537680.HKD","LU2097828474.EUR","IE00B42XCP33.USD","LU0502904849.HKD","LU0326950275.SGD","IE00B3QW5Z07.USD","LU2488822045.USD","BK4567","BK1583","LU1599440770.SGD","LU0070302665.USD","LU2097828714.EUR","LU2097828805.USD","LU2242644610.SGD","BK1161","IE00BGHQF631.EUR","LU1481011911.USD","LU1670628061.USD","BK4534","IE00BVYPNV92.GBP","LU2097828631.EUR","LU2328871848.SGD","LU0648001328.SGD","LU2505996509.AUD","BK4535","IE00BDGV0183.EUR","LU1074936037.SGD","LU1509826696.USD","LU1280957306.USD","LU0320765489.SGD","LU2592432038.USD","LU1188198961.HKD","LU0208291251.USD","IE00B64PRP62.GBP","LU2430703178.SGD","LU2097828557.USD","LU1481011671.HKD","KURE","LU0731783048.USD","BK4588","LU0980610538.SGD","LU2264538146.SGD","LU0244354667.USD","EWH","LU1064131342.USD","LU0731783394.SGD","LU0463099449.HKD","HK0000165453.HKD","LU1670627923.USD","LU1291159041.SGD","LU1201861249.SGD","LU1988902786.USD","LU2505996681.GBP","LU0157215616.USD","LU0640476718.USD","BLK","LU0455707207.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660553485","title":"CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2660553485","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660553485?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:49","pubTimestamp":1786956561,"startTime":"0","endTime":"0","summary":"Aug 17 (Reuters) - CSPC Innovation Pharmaceutical Co., Ltd. <300765.SZ>::*H1 NET PROFIT 1.3 BILLION YUAN ($192.94 million)((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 17-AUG-202608:33:31 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nRSD7jdYvX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226288253.USD","LU1813983027.USD","300765","LU0314109678.HKD","IE00B5MMRT66.SGD","LU0315179316.USD","IE00B031HY20.USD","LU1328277881.USD","BK1521","LU1951186391.HKD","LU1226287792.SGD","BK0226","IE0008369823.USD","LU0326950275.SGD","LU1226288170.HKD","LU0501845795.SGD","IE00B543WZ88.USD","LU1807302812.USD","LU1960683339.HKD","LU0880133367.SGD","LU0067412154.USD","LU1152091168.USD","LU1226287529.USD","BK1515","01093","LU1226287875.USD","IE00BZ08YS42.EUR","BK1191","SG9999004220.SGD","KURE","IE00BZ08YT58.USD","LU0140636845.USD","LU2039709279.SGD","HK0000165453.HKD","LU1008478684.HKD","LU1993786604.SGD","LU0072913022.USD","IE0008368742.USD","IE00BZ08YR35.GBP","LU1152091754.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660483149","title":"Wuxi Biologics (Cayman) Stock Rises 2.3% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2660483149","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660483149?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:31","pubTimestamp":1786955460,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rallied 2.3% to 46.16 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.3% to 25453.23.Wuxi Biologics  Inc. closed 5.4% short of its 52-week high of HK$48.78, which the company achieved Aug. 10.Trading volume totaled 26.1 million shares, compared to the 50-day average of 34.3 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1610","LU0348735423.USD","LU0516422952.EUR","LU0979878070.USD","LU0039217434.USD","LU0029874061.USD","LU0052750758.USD","KURE","LU0456846285.SGD","BK1589","SG9999002463.SGD","BK1141","LU1880383366.USD","LU0456827905.SGD","LU0051755006.USD","LU0823426480.USD","LU0856984785.SGD","LU0823426308.USD","LU0819121731.USD","LU0359201612.USD","LU0320764599.SGD","LU1242518857.USD","BK1521","LU0140636845.USD","02269","LU0128526141.USD","LU0417516902.SGD","LU0043850808.USD","LU0181495838.USD","LU0326950275.SGD","LU0327786744.USD","BK1576","LU0359202008.SGD","LU0516423091.SGD","LU3063872942.SGD","LU1688375341.USD","LU0572944931.SGD","LU0588546209.SGD","LU0417516738.SGD","LU1794554557.SGD","LU0516423174.USD","SG9999002562.SGD","LU0307460666.USD","LU0516422440.USD","LU0516422366.SGD","LU0708995583.HKD","LU1720050803.USD","IE00B0JY6N72.USD","LU1242518931.SGD","LU2039709279.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660483654","title":"WuXi Biologics Agrees to Sell 51.1% Stake in Bestchrom","url":"https://stock-news.laohu8.com/highlight/detail?id=2660483654","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660483654?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:29","pubTimestamp":1786955394,"startTime":"0","endTime":"0","summary":"WuXi Biologics agrees to sell 51.1% stake in BestchromWuXi Biologics entered a disposal arrangement to sell its 51.1% stake in Bestchrom to an independent third party.Closing is expected by December 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL5k1PMV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"WuXi Biologics Agrees to Sell 51.1% Stake in Bestchrom","news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516738.SGD","LU1720050803.USD","BK1576","BK1521","LU0516422440.USD","LU0823426480.USD","02269","LU0708995583.HKD","LU2039709279.SGD","LU0856984785.SGD","LU0326950275.SGD","LU0456827905.SGD","LU0588546209.SGD","BK1141","LU0128526141.USD","LU1242518931.SGD","LU0181495838.USD","LU0516422952.EUR","LU0456846285.SGD","LU0823426308.USD","LU0029874061.USD","BK1610","LU0043850808.USD","LU0516423174.USD","LU1242518857.USD","SG9999002562.SGD","LU0307460666.USD","IE00B0JY6N72.USD","LU0819121731.USD","LU0516423091.SGD","LU3063872942.SGD","LU0417516902.SGD","LU0052750758.USD","LU0348735423.USD","LU0327786744.USD","LU0359202008.SGD","LU0359201612.USD","LU0516422366.SGD","LU0572944931.SGD","LU1794554557.SGD","LU1880383366.USD","SG9999002463.SGD","LU0039217434.USD","KURE","LU0320764599.SGD","BK1589","LU0140636845.USD","LU1688375341.USD","LU0979878070.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110314526","title":"JPMorgan Chase & Co. Increases Stake in BEONE MEDICINES by Over 4.1 Million Shares at Approximately HKD 219.79 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1110314526","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110314526?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:51","pubTimestamp":1786708275,"startTime":"0","endTime":"0","summary":"Data from the Hong Kong Stock Exchange shows that on August 11, JPMorgan Chase & Co. increased its holdings in BEONE MEDICINES (06160) by 4,119,720 shares.The transaction was executed at an average...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443465.HKD","LU2106854487.HKD","LU0211327993.USD","LU0323591593.USD","JPM","IE00BKDWB100.SGD","LU0208291251.USD","BK4534","LU2237443382.USD","LU0070302665.USD","IE00BHPRN162.USD","IE00BDRTCR15.USD","LU2242649171.HKD","LU1668664300.SGD","LU1894683264.USD","LU1917777945.USD","BK1588","BK4550","LU0187121727.USD","LU0345770308.USD","SG9999002224.SGD","LU2456880835.USD","LU0820562030.AUD","LU1261432733.SGD","TFNS","688235","LU2746668974.SGD","LU2462157665.USD","LU2756315664.SGD","LU2054465674.USD","BK4504","IE0034235303.USD","LU0256863811.USD","LU2505996509.AUD","LU0320765489.SGD","LU2357305700.SGD","JPMO","LU0820561909.HKD","LU0868494708.USD","LU0006306889.USD","LU1719994722.HKD","LU0828237510.HKD","LU1551013425.SGD","LU2023250504.SGD","IXG","LU2430703095.HKD","LU0320765646.SGD","FNCL","IE0034235188.USD","LU1366192091.USD","LU2357627491.SGD","LU0942090050.USD","LU1116320737.USD","IE00BLSP4452.SGD","LU0215105999.USD","LU0234570918.USD","LU2328871848.SGD","LU2430703251.USD","IE00B3S45H60.SGD","LU1084165304.USD","LU1032466523.USD","LU0048584097.USD","IE00BJTD4V19.USD","LU1280957306.USD","LU1914381329.SGD","LU1894683348.USD","LU0256863902.USD","LU2211815571.USD","LU2236285917.USD","LU0106261372.USD","LU0683600562.USD","LU1145028129.USD","IE00BZ1G4Q59.USD","LU1244550577.SGD","BK4526","LU1363072403.SGD","LU0964807845.USD","KBWB","BK4516","LU0310799852.SGD","LU1670627923.USD","LU0417517546.SGD","LU0307460666.USD","LU1969619763.USD","LU1551013342.USD","IE00B775SV38.USD","LU2244417387.USD","LU0267386448.USD","LU2237443895.HKD","LU0203345920.USD","LU2381873111.SGD","LU1251922891.USD","LU1720051108.HKD","06160","BK0239","JPMLL","JPO","LU1064131342.USD","LU2756315318.SGD","LU2746668461.USD","BK1161","LU1116320901.HKD","IE00BWXC8680.SGD","LU0265550946.USD","LU2417539215.USD","LU0787776722.HKD","LU1162221912.USD","LU2552382058.USD","LU2237443549.SGD","BK1500","LU1988902786.USD","BK4207","JPX","LU0345769631.USD","IE00BJLML261.HKD","LU2592432038.USD","LU0265550359.USD","UYG","BK4533","LU2237443978.SGD","LU1974910355.USD","ONC","LU0859254822.USD","LU1770034418.SGD","LU1720051017.SGD","LU0211331839.USD","LU0106831901.USD","LU0976567544.SGD","FTXO","LU2023250330.USD","XLF","LU2552382215.SGD","LU2237443622.USD","LU2264538146.SGD","LU2552382132.HKD","LU0203347892.USD","LU0170899867.USD","BK4582","IE00BK4W5L77.USD","LU1244550221.USD","LU1629891620.HKD","LU2213496289.HKD","LU0943347566.SGD","EWH","LU1496350171.SGD","LU0689472784.USD","LU0345770993.USD","IE0034235295.USD","LU0882574139.USD","LU0868494617.USD","LU0251132253.USD","LU1303224171.USD","IYF","KURE","LU1670628061.USD","BK4139","LU0640476718.USD","LU0234572021.USD","IE00BDCRKT87.USD","IE00BN8TJ469.HKD","LU0211326839.USD","BK4588","IE00BBT3K403.USD","IE00BK4W5M84.HKD","LU0211328371.USD","IE00BFXG1179.USD","LU0345769128.USD","LU0496365809.HKD","LU1244550494.USD","LU1548497426.USD","LU2505996681.GBP","LU0971096721.USD","LU1267930490.SGD","PGF","LU1496350502.SGD","IE000M9KFDE8.USD","IE00BLSP4239.USD","LU0228659784.USD","LU0588546209.SGD","LU0149725797.USD","LU1119994496.HKD","VFH","LU2023250843.SGD","BK1583","IE00BKVL7J92.USD","IE00B1BXHZ80.USD","IE00B1XK9C88.USD","TRUF","LU0238689110.USD","IE00BYXW3230.USD","BK4585","BK4566","LU0211326755.USD","LU2430703178.SGD","LU0820561818.USD","IE00BJTD4N35.SGD","IYG","SG9999002232.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659112924","title":"Everest Medicines Appoints Yue Wang as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2659112924","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659112924?lang=en_us&edition=fundamental","pubTime":"2026-08-14 17:05","pubTimestamp":1786698311,"startTime":"0","endTime":"0","summary":"Everest Medicines appoints Yue Wang as non-executive directorEverest Medicines named Yue Wang as a non-executive director, effective Aug. 14, 2026.William Ki Chul Cho resigned as a non-executive direc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL9wlDNb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0516422952.EUR","LU0979878070.USD","LU0417516902.SGD","LU0823426308.USD","01952","LU0348735423.USD","LU2039709279.SGD","LU0327786744.USD","LU0456827905.SGD","BK1574","LU0572944931.SGD","LU0307460666.USD","LU0320764599.SGD","LU0181495838.USD","LU0417516738.SGD","LU0588546209.SGD","LU0516422366.SGD","LU1794554557.SGD","BK1141","LU0456846285.SGD","LU0823426480.USD","09606","LU0052750758.USD","LU0516422440.USD","LU0516423091.SGD","LU0359201612.USD","02269","BK1610","SG9999002562.SGD","HK0000252160.HKD","IE00B0JY6N72.USD","LU2543165471.USD","LU0819121731.USD","HK0000500386.USD","BK1521","LU0326950275.SGD","SG9999002463.SGD","LU0348825331.USD","BK1161","LU0140636845.USD","LU1242518857.USD","KURE","BK1576","LU0039217434.USD","BK1589","HK0000252152.HKD","LU0359202008.SGD","LU0029874061.USD","LU0043850808.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659846114","title":"Wuxi Biologics (Cayman) Stock Sheds 1.3% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2659846114","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659846114?lang=en_us&edition=fundamental","pubTime":"2026-08-14 16:33","pubTimestamp":1786696380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. slid 1.3% to 45.14 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.1% to 25116.85.Wuxi Biologics  Inc. closed 7.5% short of its 52-week high of HK$48.78, which the company achieved Aug. 10.Trading volume totaled 21.3 million shares, compared to the 50-day average of 34.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823426308.USD","LU0516422366.SGD","BK1589","LU0417516902.SGD","LU3063872942.SGD","SG9999002562.SGD","LU2039709279.SGD","BK1576","LU0456827905.SGD","KURE","LU0043850808.USD","LU1242518857.USD","LU1794554557.SGD","LU0140636845.USD","LU0979878070.USD","LU0588546209.SGD","LU0823426480.USD","SG9999002463.SGD","LU0348735423.USD","LU0417516738.SGD","LU0326950275.SGD","LU1242518931.SGD","LU0320764599.SGD","LU0819121731.USD","02269","LU0052750758.USD","LU0307460666.USD","LU0516423174.USD","LU0348825331.USD","BK1610","BK1521","LU0516422952.EUR","LU0572944931.SGD","LU0856984785.SGD","LU0051755006.USD","LU0516423091.SGD","LU0708995583.HKD","LU0359202008.SGD","LU1720050803.USD","LU0516422440.USD","LU0181495838.USD","BK1141","LU1688375341.USD","LU0039217434.USD","LU0456846285.SGD","LU1880383366.USD","LU0029874061.USD","IE00B0JY6N72.USD","LU0327786744.USD","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659114901","title":"What Does Akeso (SEHK:9926) China Lung Cancer Approval Mean For Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2659114901","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659114901?lang=en_us&edition=fundamental","pubTime":"2026-08-14 13:22","pubTimestamp":1786684922,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) received regulatory approval in China for ivonescimab plus chemotherapy as a first-line treatment for advanced squamous non small cell lung cancer.\nThe decision establishes ivonescimab combination therapy as a new standard of care for this patient group in China.\nThe approval follows Phase III data that were presented at ASCO and published in The Lancet, which underscores international clinical recognition.\n\nFor investors tracking how new oncology drugs and clinical data...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/what-does-akeso-sehk9926-china-lung-cancer-approval-mean-for","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/what-does-akeso-sehk9926-china-lung-cancer-approval-mean-for","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2476274720.SGD","BK1161","LU1961090484.USD","09926","KURE","LU0540923850.HKD","LU0634319403.HKD","ISBC","LU0561508036.HKD","IE00B5MMRT66.SGD","LU2476274308.USD","IE00BPRC5H50.USD","LU1794554557.SGD","LU2778985437.USD","LU0348784397.USD","LU2488822045.USD","LU0348783233.USD","LU0348827113.USD","BK1574","LU0348766576.USD","LU0348735423.USD","LU0348825331.USD","IE00B543WZ88.USD","LU0348767384.USD","LU0417516738.SGD","LU1720050803.USD","LU2399975544.HKD","LU0417516571.SGD","LU0417516902.SGD","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659016285","title":"Akari Net Loss Widens to $4.81 Million in Q2 FY26; Operating Loss Rises to $4.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659016285","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659016285?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:04","pubTimestamp":1786651489,"startTime":"0","endTime":"0","summary":"Akari net loss widens to $4.81 million in Q2 FY26; operating loss rises to $4.6 millionAkari Therapeutics posted a GAAP net loss of $4.81 million for the quarter ended June 30, 2026, widening from $1.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL84Mgx5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0167","LU0979878070.USD","LU0456846285.SGD","LU0516422952.EUR","LU0051755006.USD","LU0456827905.SGD","LU0326950275.SGD","LU0516422366.SGD","LU0708995583.HKD","LU1688375341.USD","LU0348825331.USD","LU0307460666.USD","LU1880383366.USD","SG9999002562.SGD","BK0214","LU1242518857.USD","BK4007","LU0140636845.USD","KURE","LU0181495838.USD","BK1610","LU1242518931.SGD","LU1794554557.SGD","LU0359202008.SGD","LU0516423091.SGD","LU3063872942.SGD","BK1576","LU0320764599.SGD","LU0823426480.USD","LU0588546209.SGD","LU0819121731.USD","02269","AKTX","LU0823426308.USD","BK1589","LU0359201612.USD","LU0417516902.SGD","LU0572944931.SGD","BK1141","LU0029874061.USD","300615","LU0043850808.USD","IE00B0JY6N72.USD","LU0417516738.SGD","LU2039709279.SGD","BK4139","LU1720050803.USD","LU0516423174.USD","LU0516422440.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166703578","title":"Beone Medicines Awards Over 40,000 Restricted Stock Units to Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=1166703578","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166703578?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:58","pubTimestamp":1786611511,"startTime":"0","endTime":"0","summary":"Beone Medicines Ltd (06160) has announced a new equity incentive grant. On August 7, 2026, the Compensation Committee of the Board approved the award of 40,764 restricted stock units (RSUs)...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1303224171.USD","KURE","LU2328871848.SGD","BK1161","688235","ONC","BK0239","LU1251922891.USD","BK4585","BK1500","BK1588","LU0828237510.HKD","LU0307460666.USD","LU0228659784.USD","LU1719994722.HKD","BK1583","LU0588546209.SGD","LU1969619763.USD","BK4588","BK4139","06160","BK4526","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659109132","title":"CSPC Pharmaceutical Group Stock Rallies 2.0% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2659109132","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659109132?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:32","pubTimestamp":1786609920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. rallied 2.0% to 8.85 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.2% to 25396.51.CSPC Pharmaceutical Group Ltd. closed 24% below its 52-week high of HK$11.63, which the company reached Sept. 9.The stock outperformed some of its competitors, as Sino Biopharmaceutical Ltd. fell 1.1%, SSY Group Ltd. fell 1.4%, and United Laboratories International Holdings Ltd. fell 0.8%.Trading volume totaled 105.7 million shares, compared to the 50-day average of 95.0 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU1951186391.HKD","LU1226287792.SGD","01093","HK0000165453.HKD","IE00B543WZ88.USD","LU1993786604.SGD","LU2039709279.SGD","BK1521","LU0072913022.USD","IE0008369823.USD","LU0501845795.SGD","LU0314109678.HKD","LU1807302812.USD","LU0880133367.SGD","BK1515","LU1960683339.HKD","LU1813983027.USD","LU1226287875.USD","LU1152091754.HKD","LU0315179316.USD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU1226288253.USD","LU1152091168.USD","LU0326950275.SGD","LU1226287529.USD","LU0140636845.USD","LU0067412154.USD","IE0008368742.USD","SG9999004220.SGD","LU1226288170.HKD","KURE","BK1191","LU1008478684.HKD","LU1328277881.USD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659049182","title":"Akeso's Ivonescimab Gets Third Indication Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2659049182","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659049182?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:36","pubTimestamp":1786588580,"startTime":"0","endTime":"0","summary":"Akeso  said ivonescimab has been approved in China for a third indication, according to a Wednesday filing with the Hong Kong Exchange.The approval covers the use of ivonescimab in combination with chemotherapy as a first-line treatment for patients with squamous non-small cell lung cancer .This marks the third major authorization for an ivonescimab-containing regimen in China since the molecule's initial approval in May 2024.The drug was previously approved in May 2024 for EGFR-mutated locally advanced or metastatic non-squamous NSCLC patients who progressed after EGFR TKI treatment, and in April 2025 as a first-line treatment for locally advanced or metastatic NSCLC with PD-L1-positive expression.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2476274308.USD","LU0348767384.USD","LU1961090484.USD","LU0348735423.USD","LU0561508036.HKD","IE00B543WZ88.USD","LU0348825331.USD","LU2399975544.HKD","LU0348827113.USD","LU2778985437.USD","LU0417516902.SGD","BK1574","LU1720050803.USD","IE00B5MMRT66.SGD","09926","LU0348766576.USD","LU0540923850.HKD","KURE","LU0348784397.USD","IE00BPRC5H50.USD","LU0348783233.USD","LU2488822045.USD","LU2476274720.SGD","LU0634319403.HKD","BK1161","LU0417516738.SGD","LU1794554557.SGD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","LU0359201612.USD","LU0417516738.SGD","LU1720050803.USD","LU0823426480.USD","LU1997245094.SGD","03759","LU0823426308.USD","LU0979878070.USD","LU1794554557.SGD","LU0708995583.HKD","BK1583","LU1303224171.USD","APXH","IBRN","LU0039217434.USD","LU2125910500.SGD","LU1979443071.USD","LU0516422952.EUR","LU0572944931.SGD","LU1242518931.SGD","BMED","LU1688375341.USD","LU0181495838.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0327786744.USD","XBIX","LU0140636845.USD","LU0052750758.USD","LU1880383366.USD","LU0417516902.SGD","SMCO","CXO","LU0588546209.SGD","FHLC","SG9999002562.SGD","PSIL","IE00BPRC5H50.USD","LU1251922891.USD","BK1589","LU1046422090.SGD","BBC","02359","603259","LU0456846285.SGD","LU1242518857.USD","LU0700851271.USD","LU0456827905.SGD","LU0516422440.USD","BK0216","LU2039709279.SGD","LU1808992512.USD","LU0359202008.SGD","LU3063872942.SGD","MEDI","LU1934453819.USD","LU2495084118.USD","LU0348825331.USD","BK1576","LU2488822045.USD","LU0029874061.USD","BK1610","BK1141","SG9999002463.SGD","WX","LU1997244956.HKD","LU0128526141.USD","LU2045819591.USD","LU0307460666.USD","LU0456842615.SGD","LU0348735423.USD","SURI","LU0516423091.SGD","02269","LU0348767384.USD","IE00B0JY6N72.USD","LU1969619763.USD","LU2328871848.SGD","BK1521","LU1719994722.HKD","LU0819121731.USD","LU0043850808.USD","LU0051755006.USD","LU0320764599.SGD","LU0326950275.SGD","LU0348766576.USD","LU0516423174.USD","161027","LU0516422366.SGD","IDNA","LU0611395673.USD","LU1997245177.USD","PSCH","LU2242644610.SGD","LU1770034418.SGD","LU0856984785.SGD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659547907","title":"Spero Q2 FY26 Net Loss Widens to $9.6 Million; Revenue Posts no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2659547907","media":"Reuters","labels":["executive","corporation","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659547907?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:01","pubTimestamp":1786564908,"startTime":"0","endTime":"0","summary":"Spero Q2 FY26 net loss widens to $9.6 million; revenue posts no revenueSpero Therapeutics posted a Q2 net loss of $9.6 million, widening from a $1.7 million loss a year earlier; loss per share widened","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL5QhQXl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,corporation,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","HK0000165453.HKD","IE00BGHQF748.EUR","LU2097828714.EUR","BK4585","IE00B64PRP62.GBP","LU0244354667.USD","SG9999014013.SGD","BK1589","BK4588","IE00BN0W2W23.USD","LU0502904849.HKD","LU2488822045.USD","LU2097828474.EUR","LU2210150020.SGD","SG9999014005.SGD","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","BK1161","BK1583","LU1188198961.HKD","BK4139","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SPRO","BCDF","LU0326950275.SGD","LU1969619763.USD","BK4112","LU2097828805.USD","KURE","SG9999014021.USD","LU2097828631.EUR","LU2242644610.SGD","LU0463099449.HKD","IE00B3QW5Z07.USD","LU2097828557.USD","SG9999014039.USD","NDAQ","LU2328871848.SGD","LU0455707207.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659904569","title":"Akeso Says NMPA Approves Ivonescimab for 1L Treatment of SQ-NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2659904569","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659904569?lang=en_us&edition=fundamental","pubTime":"2026-08-13 01:47","pubTimestamp":1786556839,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Says NMPA Approves Ivonescimab For 1L Treatment Of SQ-NSCLCAug 12 (Reuters)-Akeso Inc9926.HK:NMPA APPROVES IVONESCIMAB FOR 1L TREATMENT OF SQ-NSCLCFurther company coverage:9926.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0634319403.HKD","LU0348825331.USD","09926","LU1794554557.SGD","IE00BPRC5H50.USD","LU0417516902.SGD","KURE","LU0561508036.HKD","LU0417516738.SGD","LU2778985437.USD","IE00B5MMRT66.SGD","LU2399975544.HKD","LU1961090484.USD","BK1574","LU2476274720.SGD","LU0348767384.USD","LU0348766576.USD","LU0417516571.SGD","LU0348735423.USD","LU0348783233.USD","LU2476274308.USD","LU1720050803.USD","LU0348827113.USD","IE00B543WZ88.USD","LU2488822045.USD","LU0540923850.HKD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658906511","title":"CSPC Pharmaceutical Changes Trustee for 2018 Share Award Scheme to BOCI Trustee Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2658906511","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658906511?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:19","pubTimestamp":1786547956,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical changes trustee for 2018 share award scheme to BOCI Trustee Hong KongCSPC disclosed a trustee change for its 2018 Share Award Scheme, effective Aug. 12, 2026.BOCI Trustee (Hong Kon","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL7Jgsp3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226288253.USD","LU1813983027.USD","BK0012","BK0188","LU0314109678.HKD","IE00B5MMRT66.SGD","LU0315179316.USD","IE00B031HY20.USD","LU1328277881.USD","BK1521","LU1951186391.HKD","BK0183","LU1226287792.SGD","IE0008369823.USD","LU0326950275.SGD","LU1226288170.HKD","LU0501845795.SGD","IE00B543WZ88.USD","LU1807302812.USD","LU1960683339.HKD","LU0880133367.SGD","LU0067412154.USD","LU1152091168.USD","LU1226287529.USD","BK1515","01093","LU1226287875.USD","BK0015","BK1191","IE00BZ08YS42.EUR","SG9999004220.SGD","KURE","IE00BZ08YT58.USD","LU0140636845.USD","BK0278","LU2039709279.SGD","601988","HK0000165453.HKD","LU1008478684.HKD","LU1993786604.SGD","BK0028","LU0072913022.USD","IE0008368742.USD","IE00BZ08YR35.GBP","LU1152091754.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908461","title":"Summit Gains After Partner Akeso Secures China Nod for Lung Cancer Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908461","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908461?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:42","pubTimestamp":1786542133,"startTime":"0","endTime":"0","summary":"BUZZ-Summit gains after partner Akeso secures China nod for lung cancer combo** Shares of Summit TherapeuticsSMMT.Orise 3% to $15.58** Co says its partner Akeso9926.HKannounced the marketing authoriza","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N44913L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","LU0540923850.HKD","LU0348767384.USD","LU1961090484.USD","BK4139","IE00B543WZ88.USD","LU0348784397.USD","LU2476274720.SGD","BK1161","LU0417516738.SGD","LU2778985437.USD","LU0417516571.SGD","LU2476274308.USD","LU0348735423.USD","IE00B5MMRT66.SGD","LU0348783233.USD","LU2399975544.HKD","LU0348825331.USD","LU0417516902.SGD","09926","IE00BPRC5H50.USD","LU0348766576.USD","LU0634319403.HKD","SMMT","LU2488822045.USD","LU0561508036.HKD","LU1720050803.USD","BK1574","LU0348827113.USD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176354539","title":"CSPC Pharmaceutical Group Announces Change in Trustee for 2018 Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1176354539","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176354539?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:20","pubTimestamp":1786540812,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (01093) has issued a statement regarding a change in the trustee for its 2018 share award scheme.According to the plan rules, the trustee for the 2018 share award scheme...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01093","IE00B5MMRT66.SGD","KURE","LU0072913022.USD","LU2039709279.SGD","LU1152091168.USD","IE00BZ08YR35.GBP","BK1515","LU1813983027.USD","LU1807302812.USD","IE0008368742.USD","LU0315179316.USD","LU0140636845.USD","LU1328277881.USD","BK1191","HK0000165453.HKD","IE0008369823.USD","IE00B543WZ88.USD","LU1951186391.HKD","SG9999004220.SGD","IE00BZ08YT58.USD","LU1152091754.HKD","LU1226288170.HKD","IE00BZ08YS42.EUR","BK1521","LU1993786604.SGD","LU1226288253.USD","LU1226287529.USD","LU0501845795.SGD","LU0314109678.HKD","LU1226287792.SGD","IE00B031HY20.USD","LU1008478684.HKD","LU0326950275.SGD","LU1226287875.USD","LU1960683339.HKD","LU0880133367.SGD","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147433388","title":"AKESO (09926) Gains NMPA Nod for Third Indication of Its First-in-Class Bispecific Antibody, Ivonescimab, in Frontline Squamous NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=1147433388","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147433388?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:11","pubTimestamp":1786540312,"startTime":"0","endTime":"0","summary":"AKESO (09926) has announced that its independently developed, globally first-in-class bispecific antibody, Ivonescimab (marketed as Yidaifang®), has received approval from the China National Medical...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274308.USD","LU0348767384.USD","LU1961090484.USD","LU0348735423.USD","LU0561508036.HKD","IE00B543WZ88.USD","LU0348825331.USD","LU2399975544.HKD","LU0348827113.USD","LU2778985437.USD","LU0417516902.SGD","BK1574","LU1169590202.USD","LU1720050803.USD","IE00B5MMRT66.SGD","09926","LU0348766576.USD","LU0540923850.HKD","KURE","LU0348784397.USD","IE00BPRC5H50.USD","LU0348783233.USD","IPOS","LU2488822045.USD","PD","LU2476274720.SGD","LU0634319403.HKD","BK1161","LU0417516738.SGD","LU1169589451.USD","BK4023","LU1794554557.SGD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658970884","title":"Akeso - Nmpa Approves Ivonescimab for 1L Treatment of Sq-Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658970884?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:52","pubTimestamp":1786539149,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491E1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0348825331.USD","IE00BPRC5H50.USD","LU1794554557.SGD","LU0348784397.USD","09926","KURE","LU0348735423.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0348827113.USD","LU2488822045.USD","BK1161","LU0348767384.USD","LU2476274308.USD","LU2476274720.SGD","LU0348766576.USD","BK1574","LU0417516902.SGD","LU0561508036.HKD","LU2399975544.HKD","LU1720050803.USD","LU1961090484.USD","LU0348783233.USD","LU2778985437.USD","LU0540923850.HKD","LU0634319403.HKD","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}